ClinicalTrials.gg
CompletedNCT05590403Updated Mar 6, 2025Results posted

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and Placebo in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,544
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
5th of 17
1,544 · median 976
Started
2022
with 2 others
Phase 3
15 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 5th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 3, and was the 7th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at increased risk (AIR) of respiratory syncytial virus (RSV)-lower respiratory tract disease (LRTD), versus adults >=60 YOA

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Immunogenicity
  • Safety
  • Increased risk of respiratory syncytial virus lower respiratory tract disease
  • Adults aged 50-59 years of age
  • Older adults 60 years of age and above
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • Written or witnessed obtained from the participant prior to performance of any study-specific procedure.

    1. Specific inclusion criteria for all participants in Cohort 1 (Adults HA-RSV Group, Adults HA-Placebo Group, Adults AIR-RSV Group \& Adults AIR-Placebo Group)
  • A male or female participant 50-59 YOA at the time of the study intervention administration.
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy or .
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate from 1 month prior to study intervention administration until study end for this study, and
    • has a negative pregnancy test on the day of study intervention administration.

Specific inclusion criteria for participants in the Adults-HA Sub-cohort

  • Healthy participants as established by medical history and clinical examination before entering into the study.
  • Participants with chronic stable medical conditions with or without specific treatment, such as hypertension, hypercholesterolemia, or hypothyroidism, and who are not at increased risk for RSV-LRTD , are allowed to participate in this study if considered by the investigator as medically stable (no changes in the treatment or disease severity in the past 3 months).

Specific inclusion criteria for participants in the Adults-AIR Sub cohort

Participants should be diagnosed with at least 1 of the following medical conditions and have a stable condition (no changes in the treatment or disease severity in the past 3 months):

  • Chronic pulmonary disease resulting in activity restricting symptoms or use of long-term medication
  • Chronic cardiovascular disease
  • Diabetes mellitus: types 1 and 2
  • Other diseases at increased risk for RSV-LRTD disease

    • Chronic kidney disease
    • Chronic liver disease 2. Specific inclusion criteria for Cohort 2 (OA-RSV Group)
  • A male or female participant ≥60 YOA at the time of the study intervention administration.
  • Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease are allowed to participate in this study if considered by the investigator as medically stable (no changes in the treatment or disease severity in the past 3 months).
  • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the study intervention.
  • Hypersensitivity to latex.
  • Unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol. Study participants may decide to assign a caregiver to help them complete the study procedures.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine, or medical device) other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or planned use during the study period (up to Visit 4, Month 12).
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the dose of study intervention administration, with the exception of inactivated and subunit influenza vaccines or COVID-19 vaccines (fully licensed or with EUA) which can be administered up to 14 days before or from 14 days after the study intervention administration.

Note: In case an emergency mass vaccination for an unforeseen public health threat is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.

  • Previous vaccination with an RSV vaccine, including investigational RSV vaccines.
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or administration of long-acting immune modifying treatments or planned administration at any time up to the end of the study.

    • Up to 3 months prior to the study intervention administration:
    • For , this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
    • Administration of immunoglobulins and/or any blood products or plasma derivatives.
    • Up to 6 months prior to study intervention administration: long-acting immune modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device).

Other exclusions Other exclusions for all participants

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study period that will prohibit participating in the study until study end.
  • Participation of any study personnel or their immediate dependents, family, or household members.

Other exclusions for Cohort 1

  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,544 participants (actual)

Study arms

  • Experimental
    Adults HA-RSV Group

    Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

    Biological: RSVPreF3 OA investigational vaccine

  • Placebo comparator
    Adults HA-Placebo Group

    Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

    Drug: Placebo

  • Experimental
    Adults AIR-RSV Group

    Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

    Biological: RSVPreF3 OA investigational vaccine

  • Placebo comparator
    Adults AIR-Placebo Group

    Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

    Drug: Placebo

  • Experimental
    OA-RSV Group

    Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

    Biological: RSVPreF3 OA investigational vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group

    Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. The corresponding antibody titers were expressed in Estimated Dilution 60 (ED60) and were measured on blood samples collected from vaccinated subjects. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

  2. RSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV Group

    The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to 4 (\>=4).

    Time frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

  3. RSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV Group

    Serological assays for the determination of antibodies against RSV-B were performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

  4. RSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV Group

    The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.

    Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)

  5. RSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

    Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31)

  6. RSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

    The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.

    Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)

  7. RSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

    Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

  8. RSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

    The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.

    Time frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

Secondary outcomes

  1. Percentage of Participants Reporting Each Solicited Administration Site Event (Pain, Redness and Swelling)

    Assessed solicited administration site events were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema and swelling symptom = symptom reported with a surface diameter greater than 0 millimeters.

    Time frame: During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)

  2. Percentage of Participants Reporting Each Solicited Systemic Event (Fever, Headache, Muscle Pain, Joint Pain, Tiredness)

    Assessed solicited systemic events were arthralgia, fatigue, headache, myalgia and fever \[temperature equal to or above (\>=) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.

    Time frame: During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)

  3. Percentage of Participants Reporting Any Unsolicited Adverse Events (AEs)

    Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

    Time frame: During the 30-day follow up period after vaccination (vaccine or placebo administered on Day 1)

  4. Percentage of Participants Reporting Any Serious Adverse Events (SAEs) Within 6 Months of Vaccination

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

    Time frame: From the day of the vaccination up to 6 months after vaccination (vaccine or placebo administered on Day 1)

  5. Percentage of Participants Reporting Any Onset Potential Immune Mediated Diseases (pIMDs) Within 6 Months of Vaccination

    pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From the day of the vaccination up to 6 months after vaccination (vaccine or placebo administered on Day 1)

  6. Percentage of Participants Reporting SAEs Related to Study Intervention Administration Within 12 Months of Vaccination

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

    Time frame: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)

  7. Percentage of Participants Reporting pIMDs Related to Study Intervention Administration Within 12 Months of Vaccination

    pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)

  8. Percentage of Participants Reporting Any Fatal SAEs

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

    Time frame: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)

  9. RSV-A Neutralization Titers Expressed as GMT, up to One Month Post-intervention

    Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

    Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

  10. RSV-A Neutralization Titers Expressed as GMT at Month 6 and Month 12 Post-intervention

    Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

    Time frame: At 6 months and at 12 months after study intervention administration

  11. RSV-B Neutralization Titers Expressed as GMT, up to One Month Post-intervention

    Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

    Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

  12. RSV-B Neutralization Titers Expressed as GMT, at Month 6 and Month 12 Post-intervention

    Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

    Time frame: At 6 months and at 12 months after study intervention administration

  13. Frequency of RSVPreF3-specific Cluster of Differentiation (CD)4+ T Cells Expressing at Least 2 Activation Markers up to One Month Post-intervention

    Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

  14. Frequency of RSVPreF3-specific CD4+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12 Post-intervention

    Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At 6 months and at 12 months after study intervention administration

  15. Frequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, up to One Month Post-intervention

    Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

  16. Frequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12

    Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At 6 months and at 12 months after study intervention administration

07

Results

Posted May 21, 2024

Participant flow

Out of 1544 participants enrolled in this study, 1534 participants received at least one study intervention, from which 1 participant in OA-RSV group received placebo instead of RSVPreF3 OA vaccine and was excluded from the group. Therefore, the Exposed set included 1533 participants.

Participant flow — Overall Study
MilestoneAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Started383192386191381
Completed363184369180369
Not completed208171112
Withdrew: Lost to follow-up131734
Withdrew: Consent withdrawal, not due to a (s)ae46427
Withdrew: Other20220
Withdrew: Migrated / moved from the study area11031
Withdrew: Adverse event requiring expedited reporting00410

Outcome measures

PrimaryRSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. The corresponding antibody titers were expressed in Estimated Dilution 60 (ED60) and were measured on blood samples collected from vaccinated subjects. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
Reported as:
Geometric mean · Titer
RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group
TiterAdults HA-RSV GroupOA-RSV Group
RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group7906.0 (7178.1 to 8707.7)7518.9 (6843.2 to 8261.3)
Statistical analysis
  • Adults HA-RSV Group vs OA-RSV Group · Gmt ratio: 0.95 · 95% CI 0.83 to 1.09The comparison is done using the group ratio of adjusted GMT (OA-RSV/Adults-HA-RSV) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate
PrimaryRSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV Group

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to 4 (\>=4).

Time frame:
At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
RSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV Group
Percentage of participantsAdults HA-RSV GroupOA-RSV Group
RSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV Group82.8 (78.3 to 86.8)80.2 (75.6 to 84.3)
Statistical analysis
  • Adults HA-RSV Group vs OA-RSV Group · Difference in percentage: -2.65 · 95% CI -8.54 to 3.28The comparison is done using the difference of SRR (OA-RSV -Adults-HA-RSV)
PrimaryRSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV Group

Serological assays for the determination of antibodies against RSV-B were performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
Reported as:
Geometric mean · Titer
RSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV Group
TiterAdults HA-RSV GroupOA-RSV Group
RSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV Group9024.8 (8240.8 to 9883.3)8070.3 (7385.2 to 8819.1)
Statistical analysis
  • Adults HA-RSV Group vs OA-RSV Group · Gmt ratio: 0.89 · 95% CI 0.79 to 1.02The comparison is done using the group ratio of adjusted GMT (OA-RSV/Adults-HA-RSV) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate
PrimaryRSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV Group

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.

Time frame:
At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
RSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV Group
Percentage of participantsAdults HA-RSV GroupOA-RSV Group
RSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV Group78.2 (73.3 to 82.6)74.3 (69.3 to 78.8)
Statistical analysis
  • Adults HA-RSV Group vs OA-RSV Group · Difference in percentage: -3.95 · 95% CI -10.39 to 2.53The comparison is done using the difference of SRR (OA-RSV -Adults-HA-RSV)
PrimaryRSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31)
Reported as:
Geometric mean · Titer
RSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
TiterAdults AIR-RSV GroupOA-RSV Group
RSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group8925.1 (8117.9 to 9812.6)7460.7 (6786.8 to 8201.5)
Statistical analysis
  • Adults AIR-RSV Group vs OA-RSV Group · Gmt ratio: 0.84 · 95% CI 0.73 to 0.96The comparison is done using the group ratio of adjusted GMT (OA-RSV/Adults-AIR-RSV) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate
PrimaryRSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.

Time frame:
At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
RSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
Percentage of participantsAdults AIR-RSV GroupOA-RSV Group
RSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group86.8 (82.8 to 90.2)80.2 (75.6 to 84.3)
Statistical analysis
  • Adults AIR-RSV Group vs OA-RSV Group · Difference in percentage: -6.67 · 95% CI -12.26 to -1.12The comparison is done using the difference of SRR (OA-RSV -Adults-AIR-RSV)
PrimaryRSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
Reported as:
Geometric mean · Titer
RSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
TiterAdults AIR-RSV GroupOA-RSV Group
RSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group10048.6 (9218.4 to 10953.5)8073.4 (7406.4 to 8800.4)
Statistical analysis
  • Adults AIR-RSV Group vs OA-RSV Group · Gmt ratio: 0.80 · 95% CI 0.71 to 0.91The comparison is done using the group ratio of adjusted GMT (OA-RSV/Adults-AIR-RSV) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate
PrimaryRSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.

Time frame:
At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
RSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
Percentage of participantsAdults AIR-RSV GroupOA-RSV Group
RSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group81.6 (77.1 to 85.5)74.3 (69.3 to 78.8)
Statistical analysis
  • Adults AIR-RSV Group vs OA-RSV Group · Difference in percentage: -7.31 · 95% CI -13.52 to -1.09The comparison is done using the difference of SRR (OA-RSV -Adults-AIR-RSV)
SecondaryPercentage of Participants Reporting Each Solicited Administration Site Event (Pain, Redness and Swelling)

Assessed solicited administration site events were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema and swelling symptom = symptom reported with a surface diameter greater than 0 millimeters.

Time frame:
During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Each Solicited Administration Site Event (Pain, Redness and Swelling)
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Erythema11.9 (8.8 to 15.6)0.5 (0.0 to 2.9)14.5 (11.1 to 18.5)0.5 (0.0 to 2.9)12.1 (9.0 to 15.9)
Pain76.7 (72.1 to 80.8)10.5 (6.5 to 15.7)75.2 (70.5 to 79.5)14.3 (9.6 to 20.1)61.2 (56.1 to 66.1)
Swelling9.3 (6.6 to 12.7)1.0 (0.1 to 3.7)11.6 (8.6 to 15.3)0.5 (0.0 to 2.9)7.7 (5.2 to 10.8)
SecondaryPercentage of Participants Reporting Each Solicited Systemic Event (Fever, Headache, Muscle Pain, Joint Pain, Tiredness)

Assessed solicited systemic events were arthralgia, fatigue, headache, myalgia and fever \[temperature equal to or above (\>=) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.

Time frame:
During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Each Solicited Systemic Event (Fever, Headache, Muscle Pain, Joint Pain, Tiredness)
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Arthralgia26.0 (21.6 to 30.7)5.8 (2.9 to 10.1)20.8 (16.9 to 25.3)10.0 (6.1 to 15.2)12.9 (9.7 to 16.7)
Fatigue44.0 (39.0 to 49.2)17.3 (12.2 to 23.4)36.1 (31.3 to 41.2)19.5 (14.1 to 25.8)24.0 (19.8 to 28.6)
Headache35.8 (31.0 to 40.9)16.8 (11.8 to 22.8)27.7 (23.3 to 32.5)17.4 (12.3 to 23.5)21.1 (17.1 to 25.6)
Myalgia39.3 (34.3 to 44.4)5.8 (2.9 to 10.1)32.5 (27.8 to 37.4)14.2 (9.6 to 20.0)21.4 (17.4 to 25.8)
Fever3.7 (2.0 to 6.2)1.0 (0.1 to 3.7)2.6 (1.3 to 4.8)1.1 (0.1 to 3.8)1.6 (0.6 to 3.4)
SecondaryPercentage of Participants Reporting Any Unsolicited Adverse Events (AEs)

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

Time frame:
During the 30-day follow up period after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Any Unsolicited Adverse Events (AEs)
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Percentage of Participants Reporting Any Unsolicited Adverse Events (AEs)13.6 (10.3 to 17.4)13.5 (9.0 to 19.2)15.3 (11.8 to 19.3)10.5 (6.5 to 15.7)16.3 (12.7 to 20.4)
SecondaryPercentage of Participants Reporting Any Serious Adverse Events (SAEs) Within 6 Months of Vaccination

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Time frame:
From the day of the vaccination up to 6 months after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Any Serious Adverse Events (SAEs) Within 6 Months of Vaccination
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Percentage of Participants Reporting Any Serious Adverse Events (SAEs) Within 6 Months of Vaccination0.8 (0.2 to 2.3)2.1 (0.6 to 5.2)3.9 (2.2 to 6.3)2.1 (0.6 to 5.3)2.4 (1.1 to 4.4)
SecondaryPercentage of Participants Reporting Any Onset Potential Immune Mediated Diseases (pIMDs) Within 6 Months of Vaccination

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From the day of the vaccination up to 6 months after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Any Onset Potential Immune Mediated Diseases (pIMDs) Within 6 Months of Vaccination
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Percentage of Participants Reporting Any Onset Potential Immune Mediated Diseases (pIMDs) Within 6 Months of Vaccination0 (0 to 1.0)0 (0 to 1.9)1.0 (0.3 to 2.6)0.5 (0.0 to 2.9)0.8 (0.2 to 2.3)
SecondaryPercentage of Participants Reporting SAEs Related to Study Intervention Administration Within 12 Months of Vaccination

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Time frame:
From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs Related to Study Intervention Administration Within 12 Months of Vaccination
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Percentage of Participants Reporting SAEs Related to Study Intervention Administration Within 12 Months of Vaccination0 (0 to 1.0)0 (0 to 1.9)0 (0 to 1.0)0 (0.0 to 1.9)0.3 (0.0 to 1.5)
SecondaryPercentage of Participants Reporting pIMDs Related to Study Intervention Administration Within 12 Months of Vaccination

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting pIMDs Related to Study Intervention Administration Within 12 Months of Vaccination
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Percentage of Participants Reporting pIMDs Related to Study Intervention Administration Within 12 Months of Vaccination0 (0 to 1.0)0 (0 to 1.9)0 (0 to 1.0)0 (0.0 to 1.9)0.3 (0.0 to 1.5)
SecondaryPercentage of Participants Reporting Any Fatal SAEs

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Time frame:
From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Any Fatal SAEs
Percentage of participantsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Percentage of Participants Reporting Any Fatal SAEs0 (0 to 1.0)0 (0 to 1.9)1.0 (0.3 to 2.6)0.5 (0.0 to 2.9)0 (0 to 1.0)
SecondaryRSV-A Neutralization Titers Expressed as GMT, up to One Month Post-intervention

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

Time frame:
At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
Reported as:
Geometric mean · Titer
RSV-A Neutralization Titers Expressed as GMT, up to One Month Post-intervention
TiterAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Day 1768.8 (704.7 to 838.9)772.0 (677.9 to 879.1)779.5 (725.5 to 837.6)729.8 (648.6 to 821.0)775.7 (709.9 to 847.5)
Day 317925.4 (7125.6 to 8815.0)796.9 (696.4 to 912.0)8804.1 (7953.3 to 9746.0)774.7 (683.0 to 878.6)7498.8 (6759.5 to 8319.1)
SecondaryRSV-A Neutralization Titers Expressed as GMT at Month 6 and Month 12 Post-intervention

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

Time frame:
At 6 months and at 12 months after study intervention administration
Reported as:
Geometric mean · Titer
RSV-A Neutralization Titers Expressed as GMT at Month 6 and Month 12 Post-intervention
TiterAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Month 63850.7 (3448.6 to 4299.7)849.6 (748.9 to 963.9)3980.6 (3608.6 to 4391.1)854.2 (756.2 to 965.0)3846.3 (3469.7 to 4263.7)
Month 123192.9 (2855.1 to 3570.7)965.1 (846.8 to 1099.9)3075.1 (2772.2 to 3411.0)971.8 (864.6 to 1092.4)3080.4 (2764.8 to 3432.0)
SecondaryRSV-B Neutralization Titers Expressed as GMT, up to One Month Post-intervention

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

Time frame:
At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
Reported as:
Geometric mean · Titer
RSV-B Neutralization Titers Expressed as GMT, up to One Month Post-intervention
TiterAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Day 11091.1 (1000.3 to 1190.2)1197.7 (1055.7 to 1358.8)1141.4 (1050.5 to 1240.0)1167.2 (1035.0 to 1316.1)1109.1 (1020.6 to 1205.3)
Day 318971.9 (8109.6 to 9925.8)1145.3 (1012.4 to 1295.5)9943.0 (9035.8 to 10941.4)1141.8 (1007.4 to 1294.2)8169.3 (7412.6 to 9003.3)
SecondaryRSV-B Neutralization Titers Expressed as GMT, at Month 6 and Month 12 Post-intervention

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.

Time frame:
At 6 months and at 12 months after study intervention administration
Reported as:
Geometric mean · Titer
RSV-B Neutralization Titers Expressed as GMT, at Month 6 and Month 12 Post-intervention
TiterAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Month 63880.7 (3488.4 to 4317.0)1003.2 (875.5 to 1149.4)4020.8 (3635.9 to 4446.5)942.1 (825.4 to 1075.3)3710.4 (3361.0 to 4096.1)
Month 123562.8 (3176.0 to 3996.7)1218.6 (1038.8 to 1429.5)3669.9 (3287.1 to 4097.3)1153.5 (996.6 to 1335.2)3527.7 (3177.5 to 3916.4)
SecondaryFrequency of RSVPreF3-specific Cluster of Differentiation (CD)4+ T Cells Expressing at Least 2 Activation Markers up to One Month Post-intervention

Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
Reported as:
Geometric mean · CD4+ T cells/million cells
Frequency of RSVPreF3-specific Cluster of Differentiation (CD)4+ T Cells Expressing at Least 2 Activation Markers up to One Month Post-intervention
CD4+ T cells/million cellsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Day 1102.7 ± 0.9125.6 ± 0.9161.5 ± 0.6114.7 ± 0.9111.3 ± 0.9
Day 311282.5 ± 0.4167.7 ± 0.81043.6 ± 0.6131.9 ± 0.81016.9 ± 0.8
SecondaryFrequency of RSVPreF3-specific CD4+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12 Post-intervention

Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At 6 months and at 12 months after study intervention administration
Reported as:
Geometric mean · CD4+ T cells/million cells
Frequency of RSVPreF3-specific CD4+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12 Post-intervention
CD4+ T cells/million cellsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Month 6825.6 ± 0.3140.5 ± 0.8662.9 ± 0.339.2 ± 1.0763.5 ± 0.5
Month 12492.0 ± 0.6175.8 ± 0.5335.5 ± 0.759.4 ± 1.0414.1 ± 0.7
SecondaryFrequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, up to One Month Post-intervention

Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
Reported as:
Geometric mean · CD8+ T cells/million cells
Frequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, up to One Month Post-intervention
CD8+ T cells/million cellsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Day 110.1 ± 1.16.0 ± 0.915.5 ± 1.010.8 ± 1.112.0 ± 1.0
Day 3115.2 ± 1.111.9 ± 1.118.1 ± 1.14.8 ± 1.112.0 ± 1.2
SecondaryFrequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12

Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At 6 months and at 12 months after study intervention administration
Reported as:
Geometric mean · CD8+ T cells/million cells
Frequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12
CD8+ T cells/million cellsAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Month 623.1 ± 1.012.2 ± 1.127.6 ± 1.014.0 ± 1.014.8 ± 1.1
Month 1215.2 ± 1.023.0 ± 0.916.2 ± 1.06.6 ± 1.114.9 ± 1.0

Adverse events

Collected over Solicited AEs were collected from Day 1 (day of vaccination) up to Day 4 post-dose. Unsolicited AEs were collected from Day 1 up to Day 30 post-dose. SAEs and pIMDs were collected from Day 1 up to Month 6 post dose-administration. Related SAEs, related pIMDs and fatal SAEs were collected from Day 1 up to study end (Month 12).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults HA-RSV Group0/383 (0%)3/383 (0.8%)325/383 (84.9%)
Adults HA-Placebo Group0/192 (0%)4/192 (2.1%)76/192 (39.6%)
Adults AIR-RSV Group1/386 (0.3%)15/386 (3.9%)318/386 (82.4%)
Adults AIR-Placebo Group1/191 (0.5%)4/191 (2.1%)74/191 (38.7%)
OA-RSV Group0/381 (0%)9/381 (2.4%)279/381 (73.2%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
PneumoniaInfections and infestations0/3830/1923/3860/1912/381
PericarditisCardiac disorders0/3830/1920/3861/1910/381
COVID-19Infections and infestations0/3830/1920/3861/1910/381
CellulitisInfections and infestations0/3830/1921/3861/1910/381
OsteomyelitisInfections and infestations0/3830/1920/3861/1910/381
DeathGeneral disorders0/3830/1921/3861/1910/381
Abscess oralInfections and infestations0/3831/1920/3860/1910/381
ObesityMetabolism and nutrition disorders0/3831/1921/3860/1910/381
DepressionPsychiatric disorders0/3831/1921/3860/1910/381
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3831/1920/3860/1910/381
Most frequent other events
Showing 10 of 144
Most frequent other events
EventAdults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV Group
Administration site painGeneral disorders289/38320/192285/38627/191232/381
FatigueGeneral disorders166/38334/192136/38637/19192/381
MyalgiaMusculoskeletal and connective tissue disorders149/38312/192123/38627/19183/381
HeadacheNervous system disorders137/38334/192106/38633/19181/381
ArthralgiaMusculoskeletal and connective tissue disorders101/38312/19280/38619/19150/381
Injection site erythemaGeneral disorders40/3831/19255/3861/19142/381
Administration site erythemaGeneral disorders40/3831/19255/3861/19142/381
Injection site swellingGeneral disorders32/3832/19243/3861/19125/381
Administration site swellingGeneral disorders32/3830/1923/3860/1910/381
PyrexiaGeneral disorders14/3832/19211/3863/1917/381

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Adults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV GroupTotal
Mean54.8 ± 2.854.7 ± 2.855.3 ± 2.855.6 ± 2.864.1 ± 2.958.6 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Adults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV GroupTotal
Female22111918685188799
Male16273200106193734
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adults HA-RSV GroupAdults HA-Placebo GroupAdults AIR-RSV GroupAdults AIR-Placebo GroupOA-RSV GroupTotal
Hispanic or Latino4823633550219
Not Hispanic or Latino3351683231563301312
Unknown or Not Reported010012
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Mar 2023, 4 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 21, 2022
StartActual
Oct 28, 2022
Primary completionActual
Mar 13, 2023
CompletionActual
Feb 12, 2024
Results first posted
May 21, 2024
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05590403
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Oct 28, 2022
Primary completion
Mar 13, 2023
Completion
Feb 12, 2024
Results posted
May 21, 2024
Last update
Mar 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion